- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01875835
Evaluation of Neointimal Coverage of EES and BMS After Implantation in STEMI Patients by Optical Coherence Tomography (NeoCover)
Evaluation of Neointimal Coverage of Everolimus-Eluting Stent and Bare-metal Stent After Implantation in STEMI Patients by Optical Coherence Tomography
Primary percutaneous coronary intervention (PCI) represents the preferred reperfusion strategy for patients with ST-segment elevation myocardial infarction (STEMI), since it is more effective than thrombolytic regimens in reducing adverse events, including death. Drug-eluting stents (DES) are currently being widely used in patients with STEMI. The effectiveness of DES to reduce restenosis and the need for revascularization compared with bare-metal stents (BMS) has been documented in randomized controlled trials. The first-generation DESs implanted in STEMI have been associated with delayed healing and incomplete strut coverage. Therefore, in patients with implanted DES, longer duration of dual antiplatelet therapy is needed. The second-generation DESs (ZES and EES) have been improved the drug and polymer, which have been proved to improve neointima healing compared with the first generation DESs.
However, the difference of strut coverage between EES and BMS implanted in STEMI patients is unknown. In this study, we assess the neointimal coverage at 3-month and 12-month follow-up in EES and BMS implanted in patients with STEMI by optical coherence tomography.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150081
- The Second Affiliated Hospital of Harbin Medical University
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Age: 18-75 years
- Acute MI with ST-segment elevation, within 12 hours from symptoms onset.
- Length of culprit lesion≤25mm.
- Vessel size in between 2.5 and 4.0 mm.
- Signed patient informed consent.
Exclusion Criteria:
- Prior administration of thrombolytic therapy.
- Cardiogenic shock.
- Renal failure (Crea≥2.0mg/dL).
- Recent major bleeding.
- Allergy to heparin, aspirin, clopidogrel, everolimus, the polymer components of the Xience V stent, stainless steel, or contrast media.
- Left main disease
- Multi-vessel lesion
- Other hemodynamically significant lesion(s) is present in the infarct vessel (or side branches)
- Angiography demonstrates the infarct lesion to be at the site of a previously implanted stent or in bypass grafts.
- No suitable anatomy for OCT scan.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: DES
Everolimus-Eluting Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
|
|
Aktiver Komparator: BMS
Bare-Metal Stent implanted in patients with ST-segment elevation myocardial infarction (STEMI)
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Comparison of the rate of covered struts to the EES vs BMS implanted in STEMI patients by frequency domain optical coherence tomography (FD-OCT).
Zeitfenster: 3-month
|
The covered strut is defined as the strut has definite neointimal over it.
And the rate of covered struts was calculated as the number of covered struts divided the number of total struts.
|
3-month
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Comparison of the rate of covered struts to the EES vs BMS implanted in STEMI patients by FD-OCT.
Zeitfenster: 12-month
|
The covered strut is defined as the strut has definite neointimal over it.
And the rate of covered struts was calculated as the number of covered struts divided the number of total struts.
|
12-month
|
Comparison of the rate of malaposed struts to EES vs BMS implanted in STEMI patients by FD-OCT.
Zeitfenster: 3-month
|
Strut malapposition is defined as struts detached from the vessel wall > 108μm for EES and > 101μm for BMS.
The rate of malaposed struts is calculated as the number of malaposed struts divided the number of total struts.
|
3-month
|
Comparison of the rate of malaposed struts to the EES vs BMS implanted in STEMI patients by FD-OCT.
Zeitfenster: 12-month
|
Strut malapposition is defined as struts detached from the vessel wall > 108μm for EES and > 101μm for BMS.
The rate of malaposed struts is calculated as the number of malaposed struts divided the number of total struts.
|
12-month
|
Major adverse cardiovascular events (MACE)
Zeitfenster: 12-month
|
12-month
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HMUOCT-STEMI
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Xience™ V stent (Abbott Vascular, Santa Clara, California, USA)
-
Assiut UniversityNoch keine RekrutierungFemoropopliteale VerschlusskrankheitÄgypten
-
Xuanwu Hospital, BeijingNoch keine RekrutierungStreicheln | Karotisstenose | Halsschlagader-StentChina
-
The Hospital District of SatakuntaAbgeschlossen
-
Instituto Nacional de Cardiologia Ignacio ChavezBeendetKoronare Herzkrankheit (KHK) | Perkutane Koronarintervention (PCI) | Hohes BlutungsrisikoMexiko